Core Viewpoint - Shanghai Fosun Pharmaceutical Group Co., Ltd. has approved the draft of the 2025 A-share stock option incentive plan to enhance corporate governance and attract talent, aligning the interests of shareholders, the company, and its core team [1][2][5] Group 1: A-share Stock Option Incentive Plan - The board of directors approved the 2025 A-share stock option incentive plan draft and its summary, which aims to establish a long-term incentive mechanism [1][2] - The board's voting results showed unanimous support with 7 votes in favor, 0 against, and 0 abstentions [2][5] - The plan requires approval from the shareholders' meeting to be implemented [2][3] Group 2: Implementation and Management - The board also approved the implementation assessment management measures for the 2025 A-share stock option plan, which will be submitted for shareholder approval [3][4] - The board's voting results for the assessment management measures were also unanimous with 7 votes in favor, 0 against, and 0 abstentions [3][5] Group 3: Authorization for Related Matters - The board proposed to authorize itself to handle matters related to the 2025 A-share option plan, including the number of options and grant dates, subject to shareholder approval [4][5] - The authorization includes necessary actions such as signing grant agreements and applying for registration with relevant authorities [4][7] Group 4: H-share Restricted Stock Unit Plan - The board approved the draft of the 2025 H-share restricted stock unit plan, aimed at further improving corporate governance and retaining talent [5][6] - The plan will also require shareholder approval, and the board will determine the grant date after the plan is adopted [5][6] Group 5: Authorization for H-share Plan - The board proposed to authorize itself to manage matters related to the 2025 H-share restricted stock unit plan, including the number of units granted and the grant date [6][7] - The voting results for this authorization were unanimous with 7 votes in favor, 0 against, and 0 abstentions [6][8]
复星医药: 复星医药第十届董事会第七次会议(临时会议)决议公告